Big news: a FOURTH new weight management medication has just been approved, called liraglutide (brand name Saxenda). The active ingredient is the same as that in the diabetes drug Victoza. It's a glucagon-like peptide-1 (GLP-1) receptor agonist, and is taken as a once a day injection. As with ALL weight management medication, Saxenda is NEVER to be used to REPLACE healthy diet, exercise, and behavioral strategies, it is used to help SUPPORT healthy lifestyle as an 'adjunctive' (add-on, supportive) treatment for those who need help to achieve a healthier weight.
It is not recommended for certain people - those with a personal or family history of medullary thyroid carcinoma (MTC), or in patients with multiple endocrine neoplasia syndrome type 2.
4,800 patients have been studied in three clinical trials, with these results: "Results from a clinical trial that enrolled patients without diabetes showed that patients had an average weight loss of 4.5 percent from baseline compared to treatment with a placebo (inactive pill) at one year. In this trial, 62 percent of patients treated with Saxenda lost at least 5 percent of their body weight compared with 34 percent of patients treated with placebo. Results from another clinical trial that enrolled patients with type 2 diabetes showed that patients had an average weight loss of 3.7 percent from baseline compared to treatment with placebo at one year. In this trial, 49 percent of patients treated with Saxenda lost at least 5 percent of their body weight compared with 16 percent of patients treated with placebo."
The most common side effects in patients treated with Saxenda were nausea, diarrhea, constipation, vomiting, low blood sugar (hypoglycemia, when used with certain other medications) - and decreased appetite (the last is a side effect we WANT to see!)
Saxenda's serious possible side effects include pancreatitis, gallbladder disease, renal impairment, and suicidal thoughts. The medication can also raise heart rate and patients should be monitored and the medication should be discontinued in those who experience a sustained increase in resting heart rate.
Risks and benefits must always be weighed when utilizing ANY medication, and patients and their medical providers must work together as a TEAM when deciding on therapies!
http://www.fda.gov/…/Newsr…/PressAnnouncements/ucm427913.htm
Additional information: http://finance.yahoo.com/news/fda-approves-novo-nordisks-injection-221411771.html
4,800 patients have been studied in three clinical trials, with these results: "Results from a clinical trial that enrolled patients without diabetes showed that patients had an average weight loss of 4.5 percent from baseline compared to treatment with a placebo (inactive pill) at one year. In this trial, 62 percent of patients treated with Saxenda lost at least 5 percent of their body weight compared with 34 percent of patients treated with placebo. Results from another clinical trial that enrolled patients with type 2 diabetes showed that patients had an average weight loss of 3.7 percent from baseline compared to treatment with placebo at one year. In this trial, 49 percent of patients treated with Saxenda lost at least 5 percent of their body weight compared with 16 percent of patients treated with placebo."
The most common side effects in patients treated with Saxenda were nausea, diarrhea, constipation, vomiting, low blood sugar (hypoglycemia, when used with certain other medications) - and decreased appetite (the last is a side effect we WANT to see!)
Saxenda's serious possible side effects include pancreatitis, gallbladder disease, renal impairment, and suicidal thoughts. The medication can also raise heart rate and patients should be monitored and the medication should be discontinued in those who experience a sustained increase in resting heart rate.
Risks and benefits must always be weighed when utilizing ANY medication, and patients and their medical providers must work together as a TEAM when deciding on therapies!
http://www.fda.gov/…/Newsr…/PressAnnouncements/ucm427913.htm
Additional information: http://finance.yahoo.com/news/fda-approves-novo-nordisks-injection-221411771.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.